Proactive Investors - Run By Investors For Investors

Futura Medical trial on track to deliver “major value inflection point”

The first of two phase III studies of MED2005 got underway in October, treating 1,000 men at 60 centres across Europe
blue pills
The company has developed a fast-acting gel for erectile dysfunction, which will be used to treat men who can take the little blue pill

Futura Medical PLC (LON:FUM) confirmed it will deliver the results from its phase III trial for a fast-acting gel for erectile dysfunction (ED) by the end of the year, a milestone which expects to be a “major value inflection point”.

The first of two studies of MED2005 got underway in October treating 1,000 men at 60 centres across Europe. Headline data should be released towards the back-end of 2019, the company said.

WATCH: Futura Medical fully funded and on track with critical erectile dysfunction trial

Planning for a second, confirmatory final-phase analysis has been undertaken after “extensive dialogue" with regulators and opinion leaders, investors were told.

It will incorporate a US patient group, which is expected to allow Futura to make a regulatory filing in the US. It said “discussions continue” with potential commercial partners, though nothing is likely to be concluded until it has the phase III trial results are public.

Prelims

The update came alongside prelims from the healthcare business, which sharpened its focus last year to concentrate on two potential big sellers - MED2005, the ED treatment, and TPR100, a topical non-steroidal anti-inflammatory and pain killer.

Thornton & Ross, a subsidiary of German pharma STADA, is seeking UK marketing approval for the latter. In its update, Futura said it is in “ongoing discussions” with several other potential distribution partners, but added: “Any further licensing deals are expected to be after UK regulatory approval.”

Turning to the financials, the business posted a £5.89mln loss for the year ended December 31. More importantly, having raised £5.85mln last November (and with cash resources of £9.16mln at the year-end), it has the financial runway to see it through to the data readout for its ED breakthrough.  

View full FUM profile View Profile

Futura Medical PLC Timeline

Related Articles

Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
seeds in a bowl
March 07 2019
The Vancouver company is developing Omega-3 products as oil, powder or emulsion to be used as food additives

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use